Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases). Treatment decisions are further complicated by differing patient responses to analgesics, intrusive side effects, and safety / tolerability issues that are pervasive among the many analgesic drug classes (e.g., opioid analgesics, antiepileptic drugs) prescribed for cancer pain. Currently, traditional opioid analgesics, most of which are generically available, dominate the treatment of cancer pain. With the exception of costly abuse-deterrent reformulations of certain opioid analgesics, no truly novel or mechanism-based therapies have launched in recent years. As cancer survival rates continue to grow and life expectancy increases, so too do the prevalence of cancer pain and the need for more analgesic treatments that are tolerable over the long term.
GEOGRAPHY: United States
PRIMARY RESEARCH: Survey of 50 U.S. oncologists and 50 U.S. pain specialists
KEY DRUGS COVERED: Fentanyl transdermal patch (Duragesic, generics), Nucynta IR / ER (tapentadol IR / ER), oxycodone CR / ER (OxyContin, generics; Xtampza ER), pregabalin (Lyrica, generics)
KEY INSIGHTS PROVIDED:
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.